Category: Products & Tech

BD-logo - home

New FlowSmart Infusion Set Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Becton Dickinson Medical's (BD) application to begin production of its novel FlowSmart insulin infusion set, designed to improve insulin delivery with less pain. The FlowSmart insulin infusion set was developed in collaboration with JDRF and the Helmsley Charitable Trust.
0 Shares
Toujeo basal insulin -Sanofi

Sanofi’s New Basal Insulin (Toujeo) Approved by EU

The European Commission has granted Sanofi marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), for the treatment of type 1 and type 2 diabetes mellitus in adults. Toujeo is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile.
0 Shares
Minimed 508

How to Integrate New Diabetes Technology into Schools

The school was there to figure out a way to help my daughter embrace pumping without having to leave the classroom to go to the nurse a bunch of times a day. Together we eventually came up with a plan that worked, but it didn’t happen overnight. It took time, and it also required me to understand the school’s needs, point of view and accept how they might need to come up short of what my expectations at home would be.
0 Shares
Dexcom Share

Dexcom Share: A Surprising First Impression

With the Dexcom Share usage sweeping the diabetes community, my adult daughter with diabetes and I decided to experiment. She – the person with diabetes- would get one and let me look in on her life with diabetes for a while. She’d see what it was like – after all these years of independence – to have someone oversee her diabetes life. I – the parent of someone with diabetes—would see – after years of trusting her and supporting her from afar – if I could handle seeing how life goes for her minute by minute.
0 Shares
sanofi-logo

FDA Approves Toujeo, Sanofi’s New Long Acting Insulin 

The U.S. Food and Drug Administration (FDA) approved Sanofi’s new once daily long acting insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) for treatment of adults living with type 1 and type 2 diabetes. Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR.
0 Shares
Lilly - Boehringer - logo

FDA Approves Glyxambi, New Type 2 Diabetes Medication 

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’s Glyxambi for treatment of adults with type 2 diabetes. Glyxambi is the first and only diabetes treatment in the U.S. to combine the dual mechanisms of ....
0 Shares
Medtronic MiniMed 640G System

Medtronic Launches New Minimed 640G Insulin Pump (in Australia)

Medtronic, Inc. announced the global launch of the MiniMed 640G System, the next breakthrough toward an artificial pancreas. The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit, and then resume insulin delivery once sensor glucose levels recover.
0 Shares